IMLT19000, Turner, RPL-001-16, Solid Tumor, RP1, Nivolumab
Research Question:
Is the drug RP1 alone and in combination with nivolumab safe and well tolerated in
adult subjects with advanced and/or refractory solid tumors?
Basic Study Information
Purpose:
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study
of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or
refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended
Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Location: University of Rochester Medical Center
Study Reference #: IMLT19000
Lead Researcher (Principal Investigator)
Lead Researcher:
Rachael Turner
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search